The FDA has upped its stake in making sure advertisers play by the rules, launching an e-learning course aimed at teaching healthcare providers how to spot drug ads and promo materials that may be untruthful or misleading--and how to report them to the FDA.
The recent layoffs of hundreds of drug sales reps mean there are fewer people in the field calling on doctors to see what they are prescribing. But they don't have to--drugmakers have found new tools that actually can tell them more about doctors' prescribing patterns than the physicians even know themselves.
The FDA has been talking about holding pharma executives personally liable when their companies stray outside the law. The idea hasn't gained much traction, and one high-profile attempt--remember Forest Labs CEO Howard Solomon?--met a high-profile end.
People are people, they say. People have rights. Now, a U.S. appeals court has determined that sales reps are people, and their free speech rights apply on the job, even when that means talking about off-label uses of a drug. And their employers can rely on free speech to protect off-label drug marketing. Because, after all, corporations are people, too.
As anyone in pharma knows, data can be a wonderful thing. Crunching data can also be addictive, like kettle corn or tortilla chips. We here at FierceMarkets can spend hours consuming statistics about our readers and web traffic. Here are the stories that garnered the most web traffic over the past 12 months. More >>
Was Merck's marketing tie-up with the kids' movie Madagascar 3 a no good, horrible, very bad idea? Public health groups say so--and they've asked Federal Trade Commission to investigate it.
The Senate Finance Committee launched an investigation yesterday into the ties among companies that sell pain drugs, pain experts, patient advocacy groups and professional organizations, The New York Times reports.
After a series of ad agency shuffles, Pfizer is conducting an overall review of its agency work.
GlaxoSmithKline has settled almost 25,000 more Avandia cases. The deal comes after a Philadelphia judge brought in a mediator to handle settlement talks and set a deadline for wrapping up 85% of the
Johnson & Johnson's ($JNJ) long-awaited Risperdal marketing settlement is set to top $1 billion, Bloomberg's sources say. If so, that would put it in third place among off-label marketing probes,